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Alzheimer’s disease (AD) is the most common form of dementia, affecting more than 35 
million people worldwide, and lacks any effective therapy to stop or slow the disease. AD 
is characterized by progressive appearance of extracellular amyloid beta (Aβ) plaques in 
affected regions of the brain, which lead to neuronal dystrophy and death. There is 
increasing evidence, however, that Aβ is not the sole driver of disease progression. A 
functional MRI study has revealed that the blood-brain barrier (BBB), a vital regulator of 
molecular transport between the brain and vascular system comprised in part of 
microvascular endothelial cells, becomes leaky early in disease. Furthermore, analysis of 
postmortem tissue has revealed reduced angiogenic vascular growth in AD tissues. Thus, 
vascular defects may promote neuronal death by reducing perfusion and allowing 
peripheral cells to enter the brain. The mechanisms responsible for BBB breakdown have 
not been delineated, but may be influenced or driven by Aβ and neuroinflammation. 
Inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) have been previously 
established by our lab and others to be upregulated in the AD microenvironment. I 
hypothesize that Aβ and inflammatory cytokines together drive loss of vascular endothelial 
barrier function and angiogenic sprouting. To test this hypothesis, I have used an integrated 
cell culture approach combining transwell plates, 2D cell cultures, and 3D microfluidic 
devices. Dextran permeability assays in microfluidics and transwell plates demonstrate that 
Aβ conditions increase endothelial permeability. Further, western blotting of 2D cultures 
demonstrates a dose-dependent down-regulation of both platelet-endothelial cell adhesion 
molecule (PECAM) and VE-cadherin expression in response to Aβ. Since PECAM is a 
 xiii 
critical regulator of angiogenesis, I quantified changes in angiogenic sprouting in response 
to Aβ using our microfluidic platform, thus in total my data will link PECAM dysregulation 
to dual vascular pathologies in AD: loss of barrier function and reduced angiogenic growth. 
In total, my data demonstrate that Aβ and key AD cytokines effect endothelial barrier 
function and angiogenic sprouting.  Moreover, my approach combining 2D and 
physiologically relevant 3D cell cultures provides great utility for interrogating vascular 






CHAPTER 1. INTRODUCTION 
1.1 Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most common form of dementia, affecting more than 35 
million people worldwide [1]. AD clinical symptoms begin with memory loss and progress 
to include changes in behavior, decline of motor control, loss of language and eventual 
death [1]. No effective therapies have been found to stop or slow disease progression. The 
primary risk factor for AD is age, which stresses the importance for developing effective 
therapies considering the aging worldwide population [1]. In AD, amyloid beta (Aβ) 
aggregates in the brain, forming plaques and leading to tissue aberrations that can cause 
neuronal death [1]. Traditional efforts have focused on preventing this protein aggregation, 
however, recent clinical trials targeting Aβ formation have not been able to stop or slow 
disease progression [2], which suggests Aβ aggregation is not the sole driver of the disease. 
In AD, protein aggregation is accompanied by neuroinflammation and vascular 
dysfunction, two factors that can drastically influence the brain microenvironment [3, 4]. 
Vascular dysfunction, in particular, allows neurotoxic molecules and peripheral immune 
cells into the brain [4], which can further promote neuroinflammation and production of 
neurotoxic molecules [5]. Thus, a strategy to restore vascular homeostasis, may be effective 
to stop or slow disease progression. Vascular function is heavily influenced by endothelial 
cells that form blood vessels. Therefore, the objective of this thesis is to understand how 
Aβ and neuroinflammation affect microvascular endothelial cell function and how Aβ and 
neuroinflammation relate to vascular dysfunction in AD. 
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1.2 A Need to Look Beyond Amyloid Beta 
AD is characterized by the progressive appearance of extracellular amyloid beta (Aβ) 
plaques in affected brain regions [6]. Aβ is created by cleavage of amyloid precursor 
protein (APP) by first β-secretase then γ-secretase, thus releasing Aβ monomers into the 
extra-cellular compartment to aggregate and form Aβ plaques [6]. These plaques aggregate 
in extracellular sites that are affected by AD and consequently have been shown to 
stimulate neuropathology [7]. Though Aβ is a pathological marker of AD, recent clinical 
trials targeting Aβ as a therapeutic strategy have not been able to establish a working 
therapy. For example, trials targeting Aβ with a γ-secretase inhibitor resulted in accelerated 
disease progression rather than preventing disease progression [2, 8]. Furthermore, trials 
targeting Aβ for clearance using anti-Aβ monoclonal antibodies demonstrated reduced Aβ, 
but did not show significant cognitive improvement [2, 8]. More recently, trials using a β-
secretase inhibitor were stopped due to patients having continued cognitive decline and 
showing no measurable preventative effects for pathological progression of AD [8]. State-
of-the-art technology for Aβ clearance is Biogen’s new antibody, aducanumab, which 
reduces Aβ in the AD microenvironment [9]. Aducanumab has just finished phase II trials 
and is currently in phase III trials [9]. Considering the outcomes of these clinical trials and 
lack of positive results in gamma secretase inhibitor, beta secretase inhibitor and previous 
anti-amyloid antibody phase III trials, Aβ is not likely the sole driver of disease 
progression.  
Looking beyond Aβ, there are other classic pathologies observed in AD. In addition 
to Aβ plaques formation, tau protein within neurons becomes hyper-phosphorylated and 
forms intracellular neurofibrillary tangles which have traditionally been thought to aid in 
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neuronal death [7]. Other changes in the AD microenvironment involve an upregulation of 
oxidative stress, upregulation of neuroinflammation and vascular dysfunction [10]. 
Increased oxidative stress is characterized by highly reactive superoxide molecules that 
lead to increased cytotoxicity and cell death [11]. Neuroinflammation is a result of glial 
activation, where microglia and astrocytes secrete pro-inflammatory cytokines, a process 
that becomes dysregulated in AD [10]. Lastly, vascular dysfunction is characterized by  
plasma proteins and circulating peripheral immune cells leaking into the AD 
microenvironment [12]. Though multiple pathologies are observed in AD, this thesis 
focuses primarily on dysregulated cytokine levels from neuroinflammation and vascular 
dysfunction as seen in AD. 
 Looking at vascular dysfunction, functional MRI studies have demonstrated 
vascular leakiness early in AD [13]. This blood brain barrier (BBB) dysregulation is 
possibly due to Aβ or upregulated inflammatory cytokines. Further studies have shown in 
humans and AD transgenic mice, that Aβ co-localizes on capillaries which is correlated 
with cerebral amyloid angiopathy (CAA), possibly inducing endothelial cell response that 
affects BBB integrity [14]. CAA is a potential contributor to Aβ co-localization around 
blood vessels in the brain, possibly leading to  increased levels of Aβ as seen by endothelial 
cells and in turn enhancing vascular dysfunction as seen in AD [15, 16]. However, AD 
model mice do not experience the complete vascular dysfunction observed in humans [17], 
providing difficulty in quantifying vascular changes due to Aβ co-localization. 
Additionally, Neuorinflammation has been shown to be induced by Aβ aggregation [14]. 
Furthermore, human AD brain tissue studies have shown upregulation of pro-inflammatory 
cytokines in AD tissues, likely caused by neuroinflammation [4]. This is possibly leading 
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to endothelial cell functional changes or even apoptosis, causing vascular dysfunction in 
AD. Therefore, studying the BBB and how it becomes dysfunctional in response to Aβ is 
likely to yield new insight for developing a therapeutic strategy for preventing or slowing 
disease progression. 
1.3 Blood Brain Barrier Breakdown 
1.3.1 Structure and Function 
The BBB is a vital regulator of molecular transport between the brain and vascular system, 
which is comprised of complex capillary networks that include endothelial cells, pericytes 
and astrocytes [18, 19]. Endothelial cells are of particular interest because they act as the 
primary structural component of the BBB, expressing cell-cell junction proteins that are 
responsible for maintaining endothelial barriers [20, 21]. During tissue homeostasis, the 
BBB is effective at preventing neurotoxic pathogens and peripheral immune cells from 
entering the brain as well as allowing passage of water, glucose and amino acids [18, 22, 
23]. 
1.3.2 Vascular Dysfunction 
Though the BBB acts as a potent barrier against neurotoxic pathogens and peripheral 
immune cells during tissue homeostasis, most AD patients show vascular leakiness early 
during disease progression [12, 24]. Postmortem AD tissues show vascular leakiness as 
well, which suggests vascular defects may contribute to disease progression by reducing 
perfusion and allowing peripheral immune cells to enter the brain which could promote 
neuronal death [25]. Vascular defects can be divided into two major categories: 1) 
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dysregulated angiogenesis and 2) reduced barrier function. Angiogenesis is the main 
function by which endothelial cells create new vasculature [26-28]. Angiogenesis is 
characterized by endothelial cell invasion into extracellular matrix led by a tip cell where 
migration can be driven by growth factor concentration gradients [26, 27]. This mechanism 
creates the foundation for new capillaries within the brain and is dysregulated in AD as 
demonstrated by reports of AD tissues with reduced angiogenic vascular growth [29, 30]. 
Barrier function is tightly regulated by cell-cell junction proteins such as VE-Cadherin 
(VE-Cad) and zonula occludin 1 (ZO-1) in endothelial cells during tissue homeostasis, but 
becomes dysfunctionally regulated in tissues affected by Alzheimer’s pathology [12, 14, 
31, 32]. Reduced expression of junction proteins such as VE-Cad or platelet endothelial 
cell adhesion molecule (PECAM) is known to lead to increased vascular permeability or 
reduced angiogenic growth [24, 31, 33-35]. Thus, dysregulated PECAM and VE-Cad 
protein expression possibly affect the BBB by preventing vessel repair/regrowth and 
causing leaky vessels, an example of which can be seen in figure 1, respectively in AD 
[14]. Concurrently, some junction proteins are able to regulate angiogenesis [36], therefore 
junction proteins have significant angiogenic stimuli that are critical for elucidating disease 
progression. 
1.4 Junction Proteins 
1.4.1 Function and Regulation 
Endothelial cells have high expression of junction proteins in the brain microenvironment, 
which can be divided into three groups: tight junctions (TJs), adheren junctions (AJs) and 
gap junctions (GJs) [37]. TJs prevent molecular and electrical transport [24]. AJs primarily  
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Figure 1 - Illustration of BBB leakiness. A permeable capillary will allow red 
blood cells and peripheral immune cells to leak into the brain interstitial space. 
provide structural support to adjacent cells, illustrated in figure 2, and propagate 
downstream intracellular signaling based on structural and extracellular biochemical 
influences [31, 32]. GJs are selective to cell-cell passage of proteins and electrical signals, 
therefore allowing direct signal transduction from cell to cell [38]. Though all three types 
of junction proteins are highly expressed and play an important role in maintaining BBB 
integrity, AJs play a unique role in modulating various endothelial cell functions [31, 32, 
39]. Several intracellular signaling pathways such as mitogen activated protein kinase 
(MAPK) pathways are stimulated upon AJ inhibition or activation which can lead to 
angiogenesis or barrier enhancement respectively [40, 41]. A recent study demonstrated 
that Aβ downregulates expression of the TJ claudin 5, which suggests that Aβ affects 
barrier function [42]. Since several barrier promoting-signaling pathways that promote 
claudin 5 expression are mediated by AJ activation, we can conclude that Aβ 
downregulates AJ signaling [31, 43]. Two notable AJs that are potent regulators of barrier 
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function and angiogenesis modulation in endothelial cells are PECAM and VE-Cadherin 
[31, 36]. These proteins are ubiquitously expressed in endothelial cells in the BBB and 
have not been previously linked to Aβ. Therefore, probing the effects of Aβ or 
inflammatory cytokines on these proteins will provide new insight into mechanisms 
driving dysregulation of the BBB in AD. 
 
Figure 2 - Illustration of cell-cell adhesion. Junction proteins allow for cells to 
adhere to each other. 
1.4.2 VE-Cadherin and Platelet Endothelial Cell Adhesion Molecule 
PECAM and VE-Cadherin are both highly expressed in brain microvascular endothelial 
cells with the primary function of maintaining cell-cell adhesion or regulating angiogenesis 
[31, 35, 36]. VE-Cadherin is established as a potent driver of cell-cell adhesion and has 
also been shown to play a vital role in maintaining newly formed vessels [31]. VE-Cadherin 
can be stimulated via angiopoietin to increase VE-Cadherin expression or vascular 
endothelial growth factor (VEGF) to reduce VE-Cadherin expression [39]. PECAM 
primarily acts as a cell-cell adhesion protein, but can also internalize to phosphorylate 
proteins for modulating downstream angiogenic signaling via the MAPK pathway [34, 36]. 
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Downregulation of both these functions suggests PECAM expression is reduced in AD, 
leading to the reduced angiogenic vascular growth, as reported in postmortem AD tissues 
[24]. 
1.5 Alzheimer’s Disease Microenvironment  
Analysis of postmortem AD tissues has established that numerous pro-inflammatory 
cytokines are upregulated in AD [5, 44, 45]. Several of these cytokines are known to 
dysregulate endothelial function [5], suggesting that neuroinflammation has a large impact 
on endothelial cell junction protein expression. Astrocytes, upon activation, secrete 
inflammatory cytokines such as VEGF or tumor necrosis factor alpha (TNF-α), both of 
which can decrease junction protein expression [45]. Other upregulated cytokines in the 
AD microenvironment have been reported to increase the production of Aβ, thereby 
increasing plaque deposition [45]. Though inflammation can be a normal part of healing 
and secreted growth factors are necessary for cell growth [5, 44], dysregulation of cytokine 
expression in AD affects junction protein expression and Aβ aggregation, promoting 
disease progression [4, 14]. 
1.6 Contributions of this Thesis 
There is a clear clinical need for understanding the driving mechanisms that lead to vascular 
dysfunction in Alzheimer’s pathology. Since Aβ-focused strategies have not restored 
cognitive function, AD research approaches should broaden the scope to further understand 
the role that endothelial cells play as a regulator of BBB function in AD. The lack of 
knowledge base in this particular research field requires identification of core mechanisms 
driving vascular dysfunction in AD. In this thesis, I advanced understanding of how Aβ 
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and neuroinflammatory factors affect endothelial cell function which will be an essential 
step in vascular dysfunction research in the context of AD. 
 
Figure 3 - A growth region where endothelial cells have adhered to the protein 
scaffold to form an endothelial cell monolayer in a microfluidic chamber. 
In this thesis, I take the first step toward establishing culture and function measuring 
methods by utilizing a 3D microfluidic culture platform, illustrated in figure 3, to identify 
a core signaling pathway dysregulated in endothelial cells as a response to two cytokines 
upregulated in AD: VEGF and TNF-α. I use several common biological tools such as 
immunocytochemistry, western blots, dextran diffusion, ELISA and an angiogenesis assay 
that has been previously established [46]. Since endothelial cells play a central role in 
maintaining BBB function, we are interested in delineating specifically how endothelial 
cells are affected by the AD microenvironment. 
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Figure 4 - Representation of how endothelial cell intracellular signaling can 
regulate multiple functions of the BBB. 
In the following chapters, I take the following approach (conceptual illustration in 
figure 4) to identify a core signaling mechanism that is dysregulated in response to VEGF 
or  TNF-α: 
 Functional assay quantification Establish reproducibility with an existing 
microfluidic assay that was previously designed [46] to probe changes in 
endothelial barrier functions in response to Aβ, TNF- α and VEGF. An 
endothelial cell monolayer forms along a protein scaffold with several scaffold-
exposed growth regions. Quantification of barrier function was measured via 
transport across a monolayer. 
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Figure 5 - Experimental layout of the microfluidic device and how dextran will 
diffuse through the gel region. Characterization of diffusion requires an intact 
endothelial cell monolayer across the entire device to be quantified. 
 
 Adheren Junction protein expression Demonstrate differences in adheren 
junction protein expression in response to the various conditions including: 
Control, VEGF, TNF-α or Aβ. This will verify endothelial cell-cell adhesion 
protein expression and demonstrate clear structural differences in response to 
inflammatory and pathological AD biochemical stimuli.  
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Figure 6 - Demonstration of our ability to grow and identify the 3D endothelial 
monolayer that is to be quantified for protein expression. Red: PECAM, 
Green: VE-Cadherin, Blue: Dapi. Endothelial cells grow along the top and 
bottom of the channel as well as against the protein scaffold. The highlighted 
wall is a growth region as previously illustrated in figure 3. 
 Angiogenesis quantification Employ an assay previously developed to 
characterize nascent vessel formation and elongation in response to VEGF and Aβ. 
Angiogenesis can then be quantified by the length of angiogenic sprouts growing 
from the side channel towards a VEGF gradient using CMFDA live cell tracking, 
bright field and Hoechst with which to image. 
 MAPK intracellular analysis Identify MAPK signaling pathways that are 
upregulated in endothelial cells as a response to inflammatory cytokines and Aβ. 
This can help determine targets to inhibit which would ideally reverse signaling 






Figure 7 - Technique of how to identify angiogenic sprouts. Cells must be 
attached to count as a branch. Detached cells do not actually form angiogenic 
sprouts. Distances that sprouts grew into the gel region were quantified with 
identifying sprouts in this manner. Timepoints of 0 hour (before angiogenesis) 
and 48 hour (after angiogenesis) were taken to measure distance travelled 
during conditioning. 
Collectively, this thesis utilizes an array of methodologies for characterizing several 
domains of endothelial cell function in conjunction with an innovative 3D microvascular 
culture platform to probe endothelial cells with Aβ and cytokines that negatively affect the 
BBB. Utilizing this method, we found: 1) increased permeability in response to Aβ and 
cytokines, 2) junction protein expression is reduced in response to Aβ and cytokines, 3)  
Aβ causes reduced angiogenic growth, and 4) p38 MAPK signaling is upregulated in 




CHAPTER 2. “CHARTING” ENDOTHELIAL CELL FUNCTION, 
PROTEIN EXPRESSION AND SIGNALING 
2.1 Designing an Array of Experiments to Probe Endothelial Cell Function  
Endothelial cell function may be quantified in terms of four primary readouts [20, 47-49]: 
 Endothelial monolayer permeability 
 Barrier protein expression 
 Angiogenesis 
 Intracellular signaling 
In vivo experiments are regarded as the most physiologically relevant study for AD 
research [50, 51]. Because in vivo experiments in humans would be unethical, mice are 
commonly used for AD research due to their short lifespan and a need for aged test subjects. 
However, mice do not naturally suffer from dementia, therefore transgenic mice are 
required for AD research [50, 51]. And although mice have short lifespans, aging mice  
takes 1-2 years to prepare for AD studies, slowing the progress of research in this field [50, 
51]. Also, perturbation of the mouse brain microenvironment elicits responses across 
several cell types and tissues, leading to difficulty in isolating changes from a single cell 
type. In vitro cultures on the other hand provide an environment where specific changes in 
endothelial cells can be easily measured. Because of the time scale of AD research and 
difficulty in interrogating endothelial cell specific responses in vivo, we decided to utilize 
only in vitro methods for measuring changes in endothelial cell function in response to Aβ, 
TNF- α and VEGF.  
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Current methods for analyzing endothelial monolayer integrity include: transwell 
plates, Matrigel cell cultures, spheroidal cultures, microfluidic platforms and in vivo studies 
[19, 50, 52].  
Transwell plates have strong potential for measuring biochemical interactions 
between cells and have proven to be powerful for characterizing the diffusion of drugs 
through the BBB in vitro [53]. Several studies have also utilized transwell plates to measure 
the diffusion of FITC Dextran which depending on the size of the dextran, can show 
permeability of endothelial monolayers in response to biochemical stimuli [42, 53, 54]. 
Considering the benefits of this culture platform, transwell plates were an excellent method 
for measuring the diffusion of dextran through an endothelial monolayer in response to Aβ, 
TNF- α and VEGF. One way to enhance physiologic relevance of transwell plates is to 
seed a protein matrix of Matrigel or collagen gel on which the endothelial cells can grow 
into each well.   
Matrigel is a protein matrix that is comprised of primarily laminin, hyaluronic acid 
and type IV collagen, which provide a highly physiologic protein matrix for brain 
extracellular matrix [53, 55]. Many studies have demonstrated the utility of Matrigel when 
culturing neurons, microglia, endothelial cells and other components of the brain [55]. 
Therefore, BBB studies often use Matrigel as their protein matrix with which cell-cell 
interaction among endothelial cells, astrocytes and pericytes is enabled [53, 55]. The 
effective use of Matrigel is dependent on the experimental design in which it is employed, 
such as the now common microfluidic BBB on a chip model [19, 56]. Though there is 
physiologic relevance in Matrigel, problems with endothelial cell invasion into the matrix 
provided difficulties in forming endothelial monolayers, arguably a more important aspect 
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of physiologic relevance of endothelial cell cultures [57]. This was likely due to the fact 
we were using growth factor rich Matrigel, leading to a chemotactic response in endothelial 
cells to grow into the matrix. Therefore, we decided to use collagen gel due to improved 
efficacy in growing endothelial monolayers [58]. 
 Spheroids are self-assembling constructs that include endothelial cells, astrocytes 
and pericytes in the shape of a sphere [53]. This culture method is great at monitoring 
cellular interaction due to cells in physical contact with one another [53]. However, the 
spheroid does not form an endothelial monolayer that could be used to quantify endothelial 
cell function, therefore, we decided not to use this culture method for characterizing 
changes in endothelial cell function in response to Aβ, TNF- α and VEGF. 
 Microfluidic culture platforms are highly physiologic with the ability to accurately 
model the cellular microenvironment [19, 56]. Several labs focus on designing new 
innovative platforms to increase physiologic relevance of in vitro studies with respect to 
various tissues [19, 59, 60]. For example, microfluidic platforms are often used for 
multicellular cultures, including BBB studies which have complex systems such as 
electrical stimuli mimicking a brain-like microenvironment or multiple layers to accurately 
portray layers of cells [19]. Though these systems are highly physiologic, our primary 
interest is specifically understanding endothelial cell response, therefore, we cultured 
endothelial cells to form an endothelial monolayer against a protein matrix to mimic a 
micro vessel. Considering our needs, we decided to use a microfluidic platform that could 
sustain a protein matrix with side channels, a simplified version of the more complex 
systems mentioned above [46]. 
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 Several previous studies in interrogating endothelial function in the context of BBB 
function have used cell lines, particularly for brain endothelial cells, the HCMEC/D3 cell 
line [42, 56, 61]. Previously mentioned TJ studies were conducted using these cells to show 
reduced claudin 5 protein expression [42], however, cell lines are commonly regarded as 
less physiologic than primary cells due to genetic mutations that allow continuous use [56]. 
In order to enhance physiologic relevance, we decided to use human microvascular 
endothelial cells (hMVECs – detailed in the Appendix). Though these cells are harvested 
from human skin instead of the brain, they are still arguably more physiologically relevant 
than a genetically mutated cell line [56]. We primarily chose to use hMVECs because of 
prior studies utilizing our device design and hMVECs to interrogate changes in angiogenic 
growth, a metric we aim to measure [46]. Though these are not brain derived endothelial 
cells, we will establish baseline readings with which to compare to brain endothelial cells 
in future studies. 
2.2 Choosing a Concentration of Aβ for Experimental Design 
To characterize cellular changes during AD in response to Aβ, concentrations close to 
physiologic ranges should be used. Traditionally, studies probing cellular response to 
varying concentrations of Aβ (1-10µM) [42] have reached orders of magnitude higher than 
recorded physiologic ranges (5-500nM) [62, 63]. In order to characterize cell response to 
a more physiologic concentration of Aβ than previous studies, we conducted a dose 
response experiment to identify a dosage for decreased junction protein expression. 
Endothelial cells have a clear dose response to Aβ which was characterized via western 
blots and can be seen in figure 8 which utilized protocols detailed in the Appendix A.4.1. 
PECAM expression significantly decreases at concentrations of Aβ reaching 400 and 500 
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nM. However, we chose to use 300nM of Aβ for our experimental setup because we wanted 
to be able to identify combined effects of Aβ with neuroinflammatory cytokines. This way 
we could determine how cytokines sensitize endothelial cell response with Aβ. 
 
Figure 8 - Western blot analysis of hMVEC dose-response to Aβ. (A) Western 
blot showing PECAM, VE-Cadherin and α-tubulin expression of hMVEC 6-
well plate cultures in control and Aβ concentrations ranging 100nM-500nM. 
(B) Fluorescent intensity values normalized to first α-tubulin intensity then 
controls. Significant reduction in protein expression were found in PECAM 
experiments at 400nM (p = 0.026) and 500nM (p < 0.0001) and in VE-Cadherin 
experiments at 500nM (p = 0.0071). 
2.3 Preliminary Immunocytochemistry 
Before engaging the study, we also wanted to characterize differences in junction protein 
expression in endothelial cells in response to upregulated cytokines in AD, VEGF and 
TNF-α, with and without Aβ. We also wanted to confirm our cell culture methods would 
work for this experimental setup and how using Matrigel would work in our system. 
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Therefore, the purpose of this experiment was to: 1) evaluate this platform’s ability to grow 
endothelial cells against a protein scaffold to form a monolayer, 2) eliminate biochemical 
conditions for future studies based on cell loss and 3) identify Matrigel’s efficacy for 
growing endothelial monolayers in our culture platform. 
 
Figure 9 - Immunofluorescent staining for adheren junction proteins in 
hMVECs growing in 2.5mg/mL collagen and 3mg/mL Matrigel 1:1 mixture. 
Blue: Dapi. Red: Phalloidin. Green: VE-Cadherin. Purple: PECAM. Cells 
were grown for 7 days to ensure monolayer formation on all surfaces. 
Conditions were Control, 50nM Aβ, 50ng/mL VEGF, 20ng/mL TNF-α, 50nM 
Aβ + 50ng/mL VEGF and 50nM Aβ + 20ng/mL TNF-α and show respective 
junction protein expressions. Images are maximum intensity projections of the 
3D microenvironment. 
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We conducted an immunofluorescent assay (Appendix A.4.2) with devices that had 
a collagen gel and Matrigel 1:1 mixture and endothelial cells that had grown for 5 days 
then conditioned for 24 hours. Immunofluorescent images, as seen in figure 9, reveal that 
TNF-α with and without Aβ leads to cell loss in endothelial cell cultures and therefore 
decreases the total PECAM and VE-Cadherin protein expression. From this data, we 
decided that TNF-α would be our positive control for our experimental setup and testing 
TNF-α with Aβ would be redundant for our experimental setup, despite the reports of 
upregulated secretion of TNF-α in human brains [5]. Subtle changes in protein fluorescence 
can be seen in Aβ and VEGF conditions, therefore analyzing with immunocytochemistry 
in these devices is difficult. Slight morphological changes are observed, however, a lack of 
discernible differences in PECAM or VE-Cadherin protein expression drove a change in 
our methodology, where we measure protein expression only on the scaffold wall. We 
speculate cell invasion into the gel is likely caused by growth factors within the Matrigel, 
leading to endothelial cells growing towards growth factors and degrading the gel. We 
decided that devices with so much invasion into the gel region could not be used for 
analyzing fluorescent intensity of PECAM and VE-Cadherin. Rather, future experiments 
required that we form a monolayer against the gel and channel threshold to isolate a region 
that could be consistently measured for junction protein expression. We also observed that 
Matrigel could not be used for these experiments because it caused inconsistent and 
extensive cell invasion. Though Matrigel is more physiologically relevant for the brain 
microenvironment [53, 55, 64], collagen better enables endothelial monolayers to form, 
providing an ideal scaffold with which to quantify barrier function through junction protein 
expression in 3D [20]. Therefore, we used a 2.5mg/mL collagen matrix for all the following 
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experiments because it consistently is more stiff and less prone to extensive cell invasion 
[65]. 
We also wanted to ensure that our microfluidic cell culturing device was functional 
for endothelial cell growth patterns as displayed in figure 10 [37, 58]. Since endothelial 
cells grow into monolayers on surfaces, we created a 3D rendering of a z-stack to examine 
the 3D growth patterns within our device design [58]. Endothelial cells in our microfluidic 
device cell culture platform grow to form monolayers on the glass slide, the 
polydimethylsiloxane (PDMS) surface at the top of the channel and the PDMS surface of 
the posts which can be seen in figure 10. Isometric and side views of the imaging area 
clearly show that endothelial cells grow in the desired monolayer fashion in our devices 
despite the cell invasion into the gel region. We therefore, demonstrate, with preliminary 
device cultures, that our microfluidic device allows for endothelial cells to form a 
monolayer to form a barrier along the z-direction, against which we can measure barrier 
function and transport across the monoalyer. 
2.4 Dextran Diffusion in Aβ and Inflammatory Conditions 
Diffusion experiments are extensively used to determine monolayer functionality in 
endothelial cells and epithelial cells [3, 66]. Experimentally, diffusion can be characterized 
in several different ways: functional MRI, Evan’s blue dye and FITC dextran for in vivo 
experiments [13, 67, 68]; and FITC dextran and trans-endothelial electrical resistance 
(TEER) for in vitro experiments. Functional MRIs track blood flow in live brains with an 
injected radiolabel and can detect leakiness from blood vessels [13]. Evan’s blue dye can 
be injected intravenously, which cannot diffuse through healthy brain vasculature,  
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Figure 10 - Immunofluorescent images demonstrating a clear 3D growth 
pattern where hMVECs form a monolayer on the top, bottom and posts of the 
device. Blue: Dapi. Red: Phalloidin. Green: VE-Cadherin. Purple: PECAM. 
(A) Isometric view of 3D microenvironment within the device. (B) Side view 
demonstrating cells grow to form monolayers on top, bottom and on posts 
while leaving an opening in between the surfaces to generate vessel-like 
constructs. 
however, can diffuse through disease brain vasculature [68]. Evan’s blue is commonly used 
in animal models where animals are sacked and tissues are analyzed [68]. TEER is used to 
measure the electrical resistance across an endothelial monolayer, where higher electrical 
resistances indicate homeostatic barrier function in endothelial cell monolayers [54]. FITC 
dextran are fluorescent beads that come in various sizes and can diffuse through barriers 
based on the pore size [67]. Brain microvasculature has been shown to prevent 70kDa 
dextran diffusion in healthy brains, however, becomes leaky and allows 70kDa dextran 
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diffusion in brains affected by AD [51]. Therefore, we chose to use 70kDa dextran for 
characterizing the barrier function of our endothelial cell monolayers.   
 Our data, collected via protocols in Appendix A.3, are consistent with previous 
studies of endothelial monolayer permeability to 70kDa dextran, showing low diffusion in 
control samples.  We normalized fluorescent intensity to controls and our data show a 
significant increase in endothelial cell monolayer permeability in all other conditions. This 
is expected, particularly in VEGF and TNF-α conditions, because of how these proteins 
modulate adheren junction protein expression. TNF-α is extensively characterized to cause 
apoptosis in most cell types [5, 69] and it has been demonstrated in our experimental setup 
to lead to cell loss in endothelial cell cultures, thus allowing dextran diffusion. Studies have 
also characterized downstream signaling of VEGF receptor 2 activation which includes 
downregulation of VE-Cadherin expression and therefore a decrease in cell-cell adhesion, 
contributing to our hypothesis that upregulation of pro-inflammatory cytokines such as 
VEGF leads to endothelial monolayer permeability. Subsequently, Aβ has also been shown 
to interact with growth factor receptors [70, 71], including VEGF receptor 2 [70], possibly 
contributing to endothelial monolayer permeability as shown in our transwell plate 
permeability studies shown in figure 11. 
Though our transwell data demonstrates endothelial monolayer permeability to 
dextran in response to our testing conditions, the complexity of biochemical interactions 
warrants further characterization of diffusion through an endothelial monolayer in a more 
physiologic culture platform. We further characterized diffusion through an endothelial 
monolayer by culturing endothelial cells in our microfluidic device. We established an 
endothelial monolayer against the protein scaffold in our microfluidic platform and  
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Figure 11 - Dextran Diffusion shows endothelial cell monolayer permeability 
in response to inflammatory cytokines and Aβ in transwell plates. Fluorescent 
intensity of diffused dextran in various conditions with background subtracted 
and normalized to controls. Bars represent standard error of the mean with a 
significant difference established between Control and every other condition 
(p<0.05) using one-way ANOVA and Brown-Forsythe post hoc tests. 
conditioned our cells for 24 hours. Then, dextran was added to the channel with the 
monolayer and allowed to diffuse throughout the device for 18 hours. Transport across the 
monolayer is indicated by increased fluorescent intensity in the protein scaffold gel region. 
Fluorescent intensity of each imaging region was normalized to fluorescent intensity within 
the channel. These values were averaged to generate normalized fluorescence (FN) as 
displayed in figure 12B. Our microfluidic culture platform shows similar trends to our 
transwell data, and better visualizes the nature of diffusion through an endothelial 
monolayer as can be seen in figure 12A. Diffusion was quantified using fluorescent 
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intensity of dextran past a threshold of the gel layer where figure 12 clearly displays how 
far across the gel the dextran can diffuse.  
 
Figure 12 - Dextran Diffusion shows endothelial cell monolayer permeability 
in both transwell plates and microfluidic devices. (A) Fluorescent images of 
diffused dextran in various conditions. (B) Fluorescent intensity quantification 
showing diffusion through endothelial cell monolayer into the collagen gel 
region in microfluidic devices. Bars represent standard error of the mean and 
no statistical significance was established (n = 4). 
OUTCOME: This integrated characterization of dextran diffusion shows clear 
functional changes in endothelial monolayer permeability in transwell plates, however, our 
microfluidic quantification method is still ongoing. To better understand these results, we 
decided to further investigate changes in endothelial cell function by quantifying junction 




2.5 Quantification of Barrier Function 
After looking at dextran transport, a method for measuring barrier function in endothelial 
cells, we wanted to quantify protein expression of both PECAM and VE-Cad, two major 
adheren junction proteins ubiquitously expressed in endothelial cells [32, 33, 41, 57]. An 
integrated approach utilizing both traditional 2D well plate cultures for western blot 
analysis and innovative 3D microfluidic cultures to quantify differences in PECAM and 
VE-Cad protein expression across conditions.  
 Western blot quantification of adheren junction protein expression (Appendix 
A.4.1) shows inflammatory cytokine and Aβ stimulated conditions decrease PECAM and 
VE-Cad protein expression which can be seen in figure 13. Significant differences were 
observed from control to Aβ (p=0.029), TNF-α (p<0.0001), and Aβ + TNF-α (p<0.0001) 
in PECAM protein expression; and control to TNF-α (p=0.0025) and Aβ + TNF-α 
(p=0.013) in VE-Cad protein expression. A significant difference was also observed from 
VEGF to Aβ + VEGF in VE-Cad protein expression (p=0.015). This outcome is likely due 
to known influences of TNF-α and VEGF on decreasing endothelial cell junction protein 
expression [72, 73]. Also, as previously stated, Aβ has been shown to interact with growth 
factor receptors. Therefore, decreases in protein expression for Aβ conditions as shown in 
figure 13 are comprehensible as well [42]. This method utilizes 6-well plate culture 
methods which are commonly used for western blot analysis for protein expression [42]. 
This method also allows endothelial cells to form a monolayer and develop cell-cell 
adhesion. However, cells are growing on polystyrene with this method which is not as 
physiologic as a protein scaffold [19, 64]. Therefore, we decided to quantify barrier 
function using our microfluidic culture platform where endothelial cells grow against a 
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collagen scaffold in 3D to form a monolayer, establishing a more physiologic 
microenvironment [19, 64]. 
 
Figure 13 - Western blot analysis shows endothelial cell monolayer protein 
expression in 6-well plate cultures. (A) Membranes, fluorescently imaged with 
Li-Cor imaging system, show protein expression with respect to conditions and 
loading controls. (B) Quantification of PECAM protein expression in response 
to the various conditions: Vehicle, 300nM Aβ, 50ng/mL VEGF, 20ng/mL TNF-
α, 300nM Aβ+50ng/mL VEGF and 300nM Aβ+20ng/mL  TNF-α shows a trend 
where all conditions downregulate protein expression, however, no statistical 
significance was established. (C) Quantification of VE-Cad protein expression 
shows similar trend to PECAM also with no statistical significance established 
(n = 4 for all). 
Microfluidic device cultures were grown until an endothelial monolayer formed 
and later fluorescently stained for PECAM and VE-Cad (Appendix A.4.2). Representative 
images of conditions are in figure 14A, and show subtle differences in protein expression 
that cannot be qualitatively analyzed, therefore, we decided to quantify the fluorescent  
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Figure 14 - Quantification of barrier function using fluorescent intensity of a 
3D monolayer grown against the collagen scaffold. (A) Representative images 
showing monolayer against the protein scaffold quantified for each condition. 
Images are maximum intensity projections of the 3D microenvironment. (B) 
Images depict sections demonstrating front views of 3D rendered devices from 
images in part A. (C) Quantification of barrier proteins were normalized to 
cell count and demonstrates statistically significant downregulated PECAM 
expression in response to Aβ (p = 0.007), but not other conditions (n = 3). (D) 
VE-Cad quantification shows no significant changes in protein expression or 
a trend (n = 3). 
intensity of the monolayer/gel threshold region of each device’s maximum intensity 
projection image. We normalized fluorescent intensity to the number of cells contributing 
to the monolayer which was counted via DAPI staining. Quantification of PECAM and 
VE-Cad along the protein scaffold show significant decreases in protein expression in only 
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the Aβ condition in PECAM as shown in figures 14B and 14C. Other conditions did not 
establish statistical significance, however, a trend demonstrating the influence of VEGF 
and Aβ can be seen in the PECAM quantification. 
Our data show barrier protein expression, an important aspect of characterizing 
changes in endothelial cell function, is decreased in Aβ and inflammatory cytokine 
conditions. However, statistical significance could not be established in most cases, most 
likely due to the low sample size of both experiments. Nevertheless, this integrated 
approach of 2D and 3D cultures is advantageous for fully characterizing barrier function 
in endothelial cell monolayers due to the benefits of both simplicity in well plate cultures 
and microfluidic device physiologic relevance. 
2.6 Reduced Angiogenic Growth in Aβ Conditions 
Angiogenesis is another major function of endothelial cells and, as previously mentioned, 
has been shown to be downregulated in AD tissues [70, 74]. Therefore, we decided to 
interrogate changes in angiogenesis in response to VEGF and Aβ with protocols detailed 
in Appendix A.5. Cells were grown for 24-48 hours in devices to avoid cell invasion into 
the gel prior to preparation and conditioning for the angiogenesis assay, which can be 
referenced in figure 25, located in the Appendix. Quantification strategy can be seen in 
figure 15, where we measured the distance travelled by angiogenic sprouts after 48 hours 
of conditioning in each region between two posts in every device. These distances were 
measured via matlab, where we selected two points on each image for starting and finishing 
positions for branches and calculated the distance travelled with a simple distance between 
two points equation as shown below (DB stands for distance of the branch). 
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 𝐷𝐵 =  √(𝑥1 −  𝑥0)2 +  (𝑦1 −  𝑦0)2 (1) 
 
Figure 15 - Phase contrast and live cell fluorescent imaging for tracking 
angiogenic sprouting of hMVECs grown in 2.5 mg/ml collagen gel at 0 and 48 
hours for Control and VEGF stimulated conditions. Graphics demonstrate the 
method used to quantify the distances of angiogenic sprouting. 
Quantification of angiogenic growth demonstrates that Aβ decreases angiogenic 
sprouting with respect to control and VEGF conditions which can be seen in figure 16. We 
expected VEGF to have higher angiogenic growth than our control, but did not see that in 
our analysis. In fact, Previous studies have shown that this method of stimulation and 
VEGF gradients should increase angiogenic sprouting distances [46], but we did not 
observe that trend. Moreover, statistical significance was established between: control and 
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Aβ, VEGF and Aβ+VEGF, and Control and Aβ+VEGF, demonstrating a functional change 
in angiogenic growth of endothelial cells in response to Aβ. These data suggest that our 
microfluidic cell culture platform and method for quantifying angiogenic growth can model 
changes in angiogenesis with respect to inflammatory cytokines upregulated in AD and 
Aβ. 
 
Figure 16 - Quantification of angiogenic growth, as measured with the 
technique shown in figure 15, demonstrates Aβ decreases angiogenic sprouting 
distances into the gel region with respect to both Control and VEGF 
conditions. Statistical significance was established between control and Aβ (p 
= 0.005), VEGF and Aβ+VEGF (p = 0.037), and control and Aβ+VEGF (p = 
0.023) with (n = 105 growth regions from 3 devices) using one-way ANOVA 
and post hoc tests. 
Combined, endothelial monolayer permeability, junction protein expression and 
angiogenic growth are strong metrics for characterizing endothelial cell response to 
inflammatory cytokines in AD and Aβ [20, 46, 73]. However, we can further characterize 
changes in endothelial cell function by looking at intracellular signaling, since intracellular 
signaling drives several processes in cellular function [75]. We therefore concluded that 
 32 
intracellular signaling is a key component for identifying a core signaling pathway that is 
driving functional changes in endothelial cells, or, in the context of AD, pathogenesis. 
2.7 Upregulated MAPK Signaling in Aβ and Pro-Inflammatory Conditions 
Recent human Alzheimer’s post-mortem tissue studies have demonstrated upregulated p38 
and ERK MAPK signaling [76]. MAPK signaling has several pathways, of which ERK has 
been linked to upregulation of angiogenesis in endothelial cells [48, 72, 77]. However, as 
mentioned earlier, AD tissues have also shown a lack of angiogenic growth establishing 
that despite an increase in angiogenic signaling there is little new development of brain 
vasculature in AD [28, 74]. This suggests that p38 MAPK intracellular signaling changes 
in endothelial cells could be driving pathogenesis of AD, which in the context of VEGF 
and TNF-α receptor activation along with downstream effects, can be seen in figure 17. 
Therefore, we elected to conduct a MAPK intracellular signaling analysis.  
 
Figure 17 – MAPK intracellular signaling pathway in the context of VEGF 
and TNF-α receptor activation. 
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For this experiment, we collected cell lysates from endothelial cell cultures from 
both a traditional 6-well plate method and our microfluidic platform (more detailed 
methods are described in the Appendix A.6). We then followed the protocol for a Luminex 
multiplex MAPK bead-based immunoassay to quantify changes in phospho-proteins in the 
MAPK signaling pathway. Readouts were fluorescent intensity values associated with 
overall expression of each analyte. Data was processed using MATLAB to complete a 
partial least squares regression (PLSR) statistical analysis. In general, PLSR is a method 
for creating new axes called latent variables (LV) where the X variables (analytes) are 
weighted based on the measurements of each analyte. PLSR is particularly useful here 
because we have a small sample size and more analytes than readouts per condition [78, 
79] and PLSR can account for the X variables that are linearly related to each other. Using 
PLSR, we were able to identify top correlates of analytes with respect to each sample [79], 
determining which analytes are most correlated with our conditions. Figure 18 
demonstrates that in part B (partial least squares discriminant analysis, PLSDA), control 
samples are most correlated with the negative spectrum of LV1 which is organized in part 
C, and shows pc-Jun, pStat1 and p-p53 phospho-proteins are most correlated to control 
samples. Therefore, we can identify that control samples are most correlated with the c-Jun 
MAPK signaling pathway with respect to our other conditions. Conversely, Aβ, VEGF and 
Aβ+VEGF conditions show increases in pHSP-27, pErk1/2 and p-p38. We can then deduce 
that Erk and p38 MAPK signaling pathways are both upregulated, however, p38 is more 
upregulated due to HSP27 being downstream of p38 [80, 81]. Additionally, our data shows 
Aβ+VEGF samples have further p38 MAPK signaling upregulation due to a high 
correlation to the negative spectrum of LV2. As mentioned earlier, post-mortem AD tissue 
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studies have shown upregulated p38 MAPK signaling [76]. Therefore, these results match 
previous studies, likely because we conditioned endothelial cells with Aβ and the top 
cytokine correlate, VEGF [5], generating a micro-environment slightly mimicking AD. 
 
Figure 18 - Partial least squares regression of intracellular signaling MAPK 
readings. (A) Heatmap shows intensity of phosphorylated MAPK protein 
expression in harvested cells lysates in 4 conditions: Control, 50nM Aβ, 
50ng/mL VEGF and 50nM Aβ + 50ng/mL VEGF. (B) Partial least squares 
discriminate analysis of the 4 conditions shows separation of conditions along 
latent variables (LVs) 1 and 2. (C-D) Latent variables were calculated and 
show protein expression that are upregulated or downregulated with respect 
to z-score of conditions along each latent variable as shown in part (B). 
We also completed our PLSR statistical analysis including readouts from our 
positive control, TNF-α. Overall, TNF-α samples had such a strong intracellular signaling 
response that analyzing signaling correlations in other conditions was difficult. Because 
PLSR determines latent variables from the entire data set, the strong signals in TNF-α 
samples caused a major shift in the PLSDA. This led to the generation of latent variables 
that were heavily influenced by signals that were upregulated in TNF-α conditions. 
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Consequently, this caused signals from other conditions to be aligned differently within 
our latent variables, showing little separation from samples other than TNF-α. In short, 
excluding TNF-α from our PLSR analysis completely changed the correlation of analytes 
to conditions and provided a true analysis in signaling differences with respect to the subtle 
changes observed in endothelial cells in response to Aβ and VEGF. 
 
Figure 19 - Partial least squares regression of intracellular signaling MAPK 
readings. (A) Heatmap shows intensity of phosphorylated MAPK protein 
expression in harvested cells lysates in 4 conditions: Control, 50nM Aβ, 
50ng/mL VEGF and 50nM Aβ + 50ng/mL VEGF. (B) Partial least squares 
discriminate analysis of the 4 conditions shows separation of conditions along 
latent variables. (C-D) Latent variables were calculated and show protein 
expression that are upregulated or downregulated with respect to z-score of 
conditions along each latent variable as shown in part (B). 
Interested in determining signaling differences with respect to 3D versus 2D culture 
methods, we then decided to extend our PLSR analysis to samples collected from our 
microfluidic culture platform. We expected to see differences due to enhanced physiologic 
 36 
culture conditions. Our 3D data, displayed in figure 20, show similar trends where VEGF 
and Aβ+VEGF conditions were highly correlated with p38 MAPK signaling, showing  
 
Figure 20 - Partial least squares regression of intracellular signaling MAPK 
readings. (A) Heatmap shows intensity of phosphorylated MAPK protein 
expression in harvested cells lysates in 4 conditions: Control, 50nM Aβ, 
50ng/mL VEGF and 50nM Aβ + 50ng/mL VEGF. (B) Partial least squares 
discriminate analysis of the 4 conditions shows separation of conditions along 
latent variables. (C-D) Latent variables were calculated and show protein 
expression that are upregulated or downregulated with respect to z-score of 
conditions along each latent variable as shown in part (B). 
heightened phosphorylation of HSP27 and p38. However, Aβ alone did not show a 
difference in MAPK signaling from control samples, unlike the 2D signaling analysis. This 
was not expected because we quantified differences in endothelial permeability, junction 
protein expression and angiogenesis in response to Aβ, all of which indicate stressed 
intracellular signaling within our microfluidic culture platform. This deviation could be 
attributed to several different factors two of which could be: 1) the protein scaffold could 
be causing cells to exhibit reduced inflammatory response due to changes in adhesion or 
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2) most of the cells were growing on either PDMS or glass which is different from the 
polystyrene in 2D experiments. Because there are several possible influences responsible 
for the drop in p38 MAPK signaling in response to Aβ in our 3D microfluidic culture 
platform, we conclude further study and validation is required.  
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CHAPTER 3. CONCLUSION 
3.1 Contributions of This Work 
This thesis has developed an integrated methodology utilizing both traditional and 3D cell 
culture platforms to characterize endothelial cell function in response to pathologically up-
regulated proteins: 
 I began by determining a dose of Aβ that would downregulate endothelial cell 
junction protein expression and possibly in turn monolayer permeability. 
 I conducted dextran diffusion assays to quantify changes in endothelial monolayer 
permeability in response to Aβ and inflammatory cytokines. We discovered that 
Aβ, VEGF and TNF-α all increase endothelial monolayer permeability in both 
transwell culture methods.  
 I demonstrated downregulation of barrier function in response to Aβ, VEGF, and 
TNF-α in 2D cultures and Aβ in 3D endothelial monolayers in our devices 
utilizing western blot and immunocytochemistry analytical tools. 
 I determined angiogenesis is significantly downregulated in response to Aβ 
utilizing our 3D microfluidic culture platform.  
 I characterized changes in intracellular MAPK signaling in both traditional 2D 
culture and innovative 3D microfluidic culture platforms. Endothelial cell 
stimulation by Aβ and VEGF, showed upregulation of p38 MAPK signaling. 
Signaling differences in 2D versus 3D culture methods were observed, however, 
several similarities indicates that our 3D microfluidic culture platform is capable 
of conserving endothelial cell signaling.  
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Combined, these results: 1) increased permeability through an endothelial monolayer, 
2) downregulated junction protein expression, 3) decreased angiogenic sprouting, and 4) 
upregulated p38 MAPK signaling in response to Aβ, VEGF and TNF-α demonstrate an 
integrated method utilizing both traditional and more innovative culture methods. This 
thesis provides a complete framework by which changes in endothelial cell function are 
extensively characterized. This integrated approach will be useful for identifying 
upregulated signaling pathways that correspond to changes in endothelial cell function such 
as monolayer permeability or angiogenesis [48]. The identified pathways can then be 
targeted for inhibition to restore endothelial cell homeostatic function. 
3.2 Future Directions 
Based on our data, we have identified that the p38 MAPK signaling pathway is upregulated 
in response to VEGF and Aβ. Future directions include inhibiting p38 to determine if p38 
restores homeostatic endothelial cell signaling and function [75, 76]. This would 
effectively identify a therapeutic strategy for restoring endothelial monolayer homeostasis 
in the context of vascular dysfunction in AD.  
 Based on our findings and development of the 3D microfluidic culture platform, 
more complex multi-cellular models of vascular dysfunction can be established utilizing 
our microfluidic culture platform. One currently popular area of research is in designing 
microfluidic devices that accurately model the BBB [19, 56]. Many microfluidic “brain on 
a chip” platforms have already been developed, each with various levels of complexity and 
physiologic relevance [19, 56]. Each are beneficial, however, not all can be adapted for 
characterizing endothelial monolayer permeability or angiogenesis [19]. The culture 
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platform used in this thesis can be further developed to include other cells found in the 
BBB, increasing physiologic relevance [19, 56]. 
 Parallel to BBB models, improving our platform to construct a more physiologic 
microenvironment for vascular dysfunction in response to immune cell interaction is 
important for characterizing the effects of inflammation on endothelial monolayer integrity 
[82]. Inflammation is a popular research area, an area for which our microfluidic culture 
platform could easily be adapted. Much research in this area is focused on macrophage 
recruitment and activity [83, 84], and how they interact with the inflamed 
microenvironment [83, 84]. Since our device allows biochemical interactions between cells 
across the gel region, macrophages and endothelial cells could be simultaneously cultured 














APPENDIX A. MATERIALS AND METHODS 
A.1  Device Fabrication 
 Devices were fabricated out of polydimethylsiloxane (PDMS- Dow Corning 
Sylgard 184 mixed in a 10:1 ratio of elastomer base to crosslinking agent) by pouring into 
a plate containing a silicon wafer, created from common soft lithography techniques (ref 
[87]). Devices were cut out of the plate and holes were punched to form the reservoirs and 
filling ports. Devices were then suspended in DI water and autoclaved for 40 minutes on a 
liquid setting. Devices were then placed in 150mm diameter plates with feature sides faced 
up and placed in the oven overnight at 80℃ to dry. Devices were then plasma bonded to 
#1.5 glass cover slips (VWR – 48393-241) and placed back in the oven overnight at 80℃. 
Next, 1 mg/mL Poly-D-lysine (PDL) (Sigma-Aldrich) was pipetted throughout the entire 
device then placed in the incubator for 4 hours to enhance cell and collagen gel matrix 
adhesion. Afterwards, devices were rinsed 3 times with sterile culture water and placed 
back in the oven at 80℃ for 24-48 hours to dry and increase hydrophobicity. 
 
Figure 21 - Setup of various steps within device fabrication. Devices remain in 
a pseudo-sterile environment after autoclaving and maintain sterility during 
PDL treatment and cell culturing. 
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Collagen gel matrix was mixed together using type I collagen (Dow Corning - 
354236), phenol red as a pH reader, NaOH and sterile culture water. 2.5 mg/mL collagen 
gel mixture at a pH of 8 was slowly pipetted into the gel ports to fill the gel region of each 
device to avoid spillage into channels. After collagen filling, devices were placed into 
humidified chambers inside the incubator for 2 hours to allow the collagen to polymerize. 
Channels on either side of the devices were filled with microvascular endothelial cell basal 
medium (Lonza EBM-2 Cat No. CC-3156) to hydrate the collagen matrix and prepare the 
device for cell culture. 
A.2  Cell Culture  
A.2.1 Passaging 
Human microvascular endothelial cells (hMVECs Lonza – Cat No. CC-2543) were 
received at passage 3 and expanded to passage 6 in endothelial growth medium (Lonza 
EGM-2MV Cat No. CC-3202) via common cell culture methods. At passage 6 cells were 
cryogenically frozen until needed. When cells were needed for cell culture, a passage 6 vial 
was thawed and expanded. Cells for culture were used from passages 7-9 which maintained 
proliferation and endothelial function up to passage 10.  
 Upon cells reaching 70-90% confluency, cells were trypsinized (Sigma-Aldrich 
Trypsin-EDTA Solution Cat No. T3924-100ML), centrifuged and resuspended in 
endothelial growth medium to a density of 2.5 million cells/mL.  
 Time lapse angiogenesis experiments used live cell stain CellTracker Green 
CMFDA (Thermo Fisher Scientific Cat. No. C2925) at 1μg/mL and Hoechst 33342 
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(Thermo Fisher Cat. No. H3570) at 100ng/mL in the flask before cell seeding. These stain 
concentrations had no noticeable effect on cell survivability during culturing in devices. 
A.2.2 Seeding Cells into Devices 
To prepare the device for cell seeding, volumes specified below were pipetted into channel 
reservoirs to form a pressure gradient against the gel region on the cell side. This led to a 
small amount of flow across the gel region to ensure cell growth along the protein matrix. 
Devices were placed in the incubator and cells were allowed to flow through the channel 
until flow reached equilibrium and cells adhered to the protein matrix (about 2 hours). 
Endothelial growth medium was then added to top off the reservoirs to avoid cell death and 
devices were placed in the incubator overnight.  
 Medium in devices was replaced every 24 hours for the duration of their use. 
Cells were allowed to grow for various amounts of time: 24-48 hours for angiogenesis 
experiments, 72 hours for dextran and immunofluorescence experiments and 72+ hours for 
intracellular signaling experiments. Progressive lumen development and angiogenic 
invasion could be seen in longer growth periods, thus why angiogenesis and dextran 
experiments were completed with a lower growth period after cell seeding. Devices were 
then conditioned with: vehicle, Aβ, VEGF or Aβ+VEGF after the respective growth period 
for each experiment. 
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Figure 22 – Demonstration of the technique for cell seeding into devices 
A.3  Dextran Permeability  
Dextran experiments were conducted after a 72 hour growth period, when sufficient cell 
growth forms a cell monolayer against the collagen scaffold. Condition was induced and 
left to incubate for 4 hours to establish flow and pressure equilibrium. 1 µL of concentrated 
5 mg/mL dextran was then added to one reservoir on the cell side and 1 µL of EBM was 
added to the opposite channel to maintain an equal pressure gradient. After the addition of 
dextran, devices were allowed to incubate overnight. Fluorescent images were taken at 18 
hours with our fluorescent microscope (Zeiss Microscopy) across the entire device. Images 
were processed with Matlab (Mathworks) to determine fluorescent intensity of the gel 
region versus the cells channel. Normalized fluorescent intensity was calculated with the 
following equation: 
𝐹𝑁 =  
𝐹𝐶ℎ𝑎𝑛𝑛𝑒𝑙−𝐹𝐺𝑒𝑙
𝐹𝐶ℎ𝑎𝑛𝑛𝑒𝑙
                                                          (2) 
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Figure 23 - Approximate regions for fluorescent intensity readings for dextran 
diffusion. 
A.4  Junction Protein Quantification  
A.4.1 Western Blots 
Cells were seeded at 1x105 cells/well in 6-well plates and grown to 90% confluence. Cells 
were then conditioned with: Vehicle, Aβ, VEGF, TNF-α, Aβ+VEGF or Aβ+ TNF-α for 24 
hours. Cell lysis buffer was mixed using RIPA buffer (Boston BioProducts – Cat No. BP-
115) with complete mini protease inhibitor tablets (Sigma Aldrich – Cat No. 
11836153001), phosphatase inhibitor cocktail 2 (Sigma Aldrich – Cat No. P5726-5ML) 
and phosphatase inhibitor cocktail 3 (Sigma Aldrich – Cat No. P0044-5ML). Plates were 
transferred from the incubator onto ice, aspirated for the medium and rinsed with cold 1x 
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PBS (Corning – Cat No. 21040CM) once. Wells were aspirated and 140 µL of cell lysis 
buffer was added to the top of each well. Cells were then detached with a cell scraper and 
pipetted to micro-centrifuge tubes and placed on an inverter at 4℃ for 10 minutes. Lysates 
were then centrifuged at 4℃ and carefully pipetted into different tubes to discard cell 
debris. Lastly, lysates were stored in a -80℃ freezer. 
 Common western blotting buffers such as 10X tris buffered saline with Tween® 20 
(TBST), running buffer and transfer were pre-made before conducting a western blot 
experiment. The following table details how these reagents were mixed.  
Table 1 - Mixing ratios for creating common western blotting buffers. 
Reagents for creating buffers include trizma base (Sigma Aldrich – Cat No. 
T1503-5KG), glycine (Alpha Aesar – Cat No. J64365-A1), 20% SDS (Sigma 
Aldrich – Cat No. 05030-500ML-F) and NaCl (Aldon Corp SE – Cat No. 
SS0450-500G). 
 
Blots were performed with homemade gels. 8 µg of each lysate was mixed with 4x 
Laemmli sample buffer (Bio-Rad – Cat No. 1610747) mixed 9:1 with β-Mercaptoethanol 
(BME, Sigma Aldrich – Cat No. M6250-100ML) and boiled for 5 minutes. Samples were 
then pipetted into lanes on the gel and left to run for 150 minutes at 80 volts. After running 
gels were rinsed in transfer buffer and protein was then transferred to PVDF membanes 
(GE Healthcare – Cat No. 10600023) for 75 minutes at 100 volts. Membranes were then 
blocked for 1 hour using Li-Cor blocking buffer (LI-COR Biosciences – Cat No. 927-
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50003) and incubated in PECAM primary antibody from mouse (Cell Signaling 
Technologies – Cat No. 3528S), VE-Cadherin primary antibody from Rabbit (Cell 
Signaling Technologies – Cat No. 2500S) and α-tubulin primary antibody from mouse 
(Sigma-Aldrich – Cat No. T6074-200UL) suspended in Li-Cor blocking buffer overnight 
at 4℃. Membranes were then washed with 1x TBST and incubated in Alexa Fluor 680 
anti-mouse (Thermo Fisher Scientific– Cat No. A-21058) and Alexa Fluor 790 anti-Rabbit 
(Thermo Fisher Scientific – Cat No. A11369) secondary antibodies for 1 hour at room 
temperature on a rocker. Membranes were then washed again with 1x TBST and imaged. 
Fluorescent intensity was measured within Image Studio software (LI-COR Biosciences) 
and processed with Matlab. 
A.4.2 3D Barrier Immunofluorescence 
Devices were given 72 hours for cells to grow and form a complete monolayer against the 
collagen gel matrix. Cells in devices were then conditioned with: Vehicle, 300nM Aβ, 
50ng/mL VEGF or 300nM Aβ + 50ng/mL VEGF and left in the incubator for 24 hours. 
Afterwards, devices were rinsed with 1X PBS and crosslinked by flowing 4% 
paraformaldehyde (Electron Microscopy Sciences – Cat No. 15700) through the channels 
for 15 minutes. Devices were then rinsed with 1X PBS twice and solubilized with 0.1% 
Triton X (Sigma Aldrich – Cat No. X100-100ML) for 10 minutes. Devices were rinsed 
once with 1X PBS and blocked for 1 hour with blocking buffer: 5% BSA (VWR – Cat No. 
97061-422) in 1X PBS, + 3% goat serum (Sigma Aldrich – Cat No. G 9023-10ML). After 
blocking, devices were incubated at 4℃ overnight in VE-Cadherin and PECAM primary 
antibodies suspended in washing buffer: 0.5% BSA in 1X PBS. The next day, the primary 
antibody was pipetted out of the device and rinsed 5 times with washing buffer. Cells were 
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then incubated in Alexa Fluor 488 goat anti-rabbit (Thermo Fisher Scientific – Cat No. A-
11008) and Alexa Fluor 555 goat anti-mouse (Thermo Fisher Scientific – Cat No. A-
21422) secondary antibodies suspended in washing buffer at room temperature for 2 hours. 
Devices were rinsed and counter stained with DAPI and suspended in washing buffer for 
1 hour at room temperature. Final washing consisted of washing with washing buffer three 
times and PBS twice. Devices were then imaged with our fluorescent microscope and 
processed using Matlab to acquire protein expression fluorescent intensities of the 
endothelial cell monolayers in the various conditions. 
 
Figure 24 - Highlights the approximate areas where endothelial cells interact 
with the collagen protein matrix and form a monolayer for quantification. 
A.5  Angiogenic Growth Measurement  
Devices were given 24-48 hours to grow and form a monolayer against the collagen gel 
matrix. Cells were treated with 100ng/mL Hoechst for 45 minutes then imaged for a 0 hour 
timepoint. After imaging, devices were conditioned with: Vehicle, Aβ, VEGF or Aβ + 
VEGF with a VEGF gradient across the gel for the cells to grow towards. Conditions and 
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the VEGF gradient were suspended in VEGF-depleted EGM-2MV. Equal volumes were 
applied to both channels to ensure pressure equilibrium and prevent mechanical stimuli 
induced angiogenic sprouting. Figure 25 demonstrates the conditioning strategy for this 
experiment. Conditioned medium was replaced every 24 hours and cells were imaged again 
after 48 hours of conditioning. Angiogenic growth distances and branching were then 
quantified using Matlab. 
 
Figure 25 - (A) Table showing conditioning strategy for both channels in the 
angiogenesis assay. (B) Demonstration of pipetting strategy for maintaining 
pressure equilibrium during conditioning. 
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A.6  Phosphorylated Protein Analysis  
Phospho-protein analysis was completed in both 2D and 3D cultures using similar 
protocols.  2D cultures were seeded at 1x105 cells/mL in 6-well plates and grown to 90% 
confluence. Cells were starved with EBM-2 for 1 hour then were conditioned with: 
Vehicle, 300nM Aβ, 20ng/mL VEGF or 300nM Aβ + 20ng/mL VEGF for 15 minutes at 
37℃. Plates were transported out of the incubator to an ice bucket and aspirated. Wells 
were rinsed with cold 1X PBS and aspirated again, followed by adding, to each well, 140 
μL of Bio-plex lysis buffer: Cell Lysis Buffer (Bio-Rad – Cat No. 171304012), complete 
mini protease inhibitor tablet, Bio-Rad Factor 1 (Bio-Rad - in kit), Bio-Rad Factor 2 (Bio-
Rad – in kit) and phenylmethylsulfonyl fluoride (Sigma Aldrich - Cat No. P7626-1G) in 
dimethyl sulfoxide (Sigma Aldrich – Cat No. D2650-100ML). Cells were detached with a 
cell scraper and lysates were transferred to micro-centrifuge tubes. Tubes were placed on 
an inverter at 4℃ for 10 minutes. Lysates were then centrifuged at 4℃ and carefully 
pipetted into different tubes to discard cell debris. Lastly, lysates were stored in a -80℃ 
freezer. 
 3D lysates were collected in a similar protocol. Cells were grown in both channels 
of devices and conditioned for 10 minutes. Devices were transferred to an ice bucket and 
rinsed for 2 minutes with cold 1X PBS. 40 μL of Bio-plex lysis buffer was added to each 
channel and incubated at 4℃ on ice for 1 hour. Lysates were then collected with the same 
protocol as 2D lysates. 
 To prepare lysates for analysis, a bicinchoninic acid assay (BCA, Thermo Fisher 
Scientific – Cat No. 23225) was conducted to identify protein concentration for each lysate. 
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Lysates were then used to conduct a linear range experiment for the 10-Plex MAPK/SAPK 
Signaling Magnetic Bead Kit (EMD Millipore – Cat No. 48-660MAG) with which 0.75μg 
and 1μg were found to be optimal loading masses for protein content in 2D and 3D lysates 
respectively. The MAPK/SAPK assay was completed by closely following the 
experimental protocol included with the kit and wells were read by our MAGPIX® 
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